Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Blood biomarkers confirm subjective cognitive decline (SCD) as a distinct molecular and clinical stage within the NIA-AA framework of Alzheimer´s disease

17 Apr 2025

Abstract excerpt

Subjective cognitive decline (SCD) is proposed as an indicator of transitional disease stage 2 in the Alzheimer's disease (AD) continuum. However, molecular and particularly longitudinal fluid biomarker data for this stage are still limited. This study aimed to determine whether blood-based biomarkers in amyloid-positive individuals with SCD (A + SCD) support the notion of stage 2 as a distinct stage between...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer's disease research and treatments
Share to Dementia and Cognitive Impairment Research
Share to Nutritional Studies and Diet

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40247130
DOI: 10.1038/s41380-025-03021-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Blood biomarkers confirm subjective cognitive decline (SCD) as a distinct molecular and clinical stage within the NIA-AA framework of Alzheimer´s diseasePMID 40247130Read ↗

Plasma biomarker levels and cognitive decline in a heterogenous community-based cohort with multiple comorbiditiesSemantic proximity Read ↗

Plasma biomarkers identify older adults at risk of Alzheimer's disease and related dementias in a real‐world population‐based cohortSemantic proximity Read ↗

Objective subtle cognitive decline and plasma phosphorylated tau181: Early markers of Alzheimer's disease‐related declinesSemantic proximity Read ↗

Association of plasma biomarkers of Alzheimer's disease and related disorders with cognition and cognitive decline: The MYHAT population‐based studySemantic proximity Read ↗

Identification of Novel Biomarkers for Alzheimer’s Disease and Related Dementias Using Unbiased Plasma ProteomicsSemantic proximity Read ↗

Clinical and demographic factors modify the association between plasma phosphorylated tau-181 and cognitionSemantic proximity Read ↗

Blood Biomarkers of Alzheimer's Disease and Cognition: A Literature Review.Semantic proximity Read ↗

Blood-Based Biomarkers in Alzheimer's Disease: Advancing Non-Invasive Diagnostics and PrognosticsSemantic proximity Read ↗

The association of blood-based biomarkers of neuropathology with cognitive performance and incident dementia in a diverse, nationally-representative sample of US adultsSemantic proximity Read ↗

Blood-Based Biomarkers in Alzheimer’s Disease: Advancing Non-Invasive Diagnostics and PrognosticsSemantic proximity Read ↗

Biomarker-based staging of Alzheimer disease: rationale and clinical applicationsSemantic proximity Read ↗

Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measuresSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.